The Netherlands respiratory devices market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to Increase in prevalence of respiratory diseases.
Respiratory devices are clinical devices that are utilized to help patients who are suffering from respiratory issues and can't achieve sufficient oxygen levels to support life. Chronic respiratory diseases are chronic diseases that affect the airways and different parts of the lungs. A portion of the major preventable chronic respiratory disorders include chronic obstructive pulmonary disease (COPD), asthma, sleep apnea, and tuberculosis.
As per the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is a major health concern and is one of the major causes of death worldwide. Technologically advanced medical devices and effective medications have become key to the management of COPD and other respiratory disorders. In the current healthcare scenario, respiratory health is of paramount importance. For instance, asthma is a serious debilitating disease, and thus requires the administration of treatment drugs for asthma.
The COVID-19 virus has tainted more than a quarter of a million people internationally. With the proceeded spread of this infection that can cause pneumonia and difficulty in breathing, hospitals are facing a limited supply of ventilators. The impact of the COVID-19 crisis is expected to further accelerate the growth of the respiratory devices market.
The report on the Netherlands respiratory devices market includes an assessment of the market, trends, segments, and geography markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Respiratory Devices Market - Netherlands Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Types (Diagnostic and Monitoring Devices [Spirometers, Sleep Test Devices, Peak Flow Meters, and Others], Therapeutic Devices [Ventilators, Inhalers, CPAP Devices and Others], and Disposables {Masks, Breathing Circuits, and Others}) |
Country Scope |
The Netherlands |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
GlaxoSmithKline PLC; DeVilbiss Healthcare LLC,; GE Healthcare; Dragerwerk AG, ; Fisher & Paykel Healthcare Ltd,; and Getinge AB. |
Based on types, the market is divided into diagnostic and monitoring devices, therapeutic devices and disposables. The diagnostic and monitoring devices segment is further classified as spirometers, sleep test devices, peak flow meters, and others. The therapeutic devices segment is further segmented into ventilators, inhalers, CPAP devices, and others. The disposables segment is further segmented into masks, breathing circuits, and others.
The ventilators sub-segment is estimated to account for a significant share of the market. Ventilators demand has been steadily increasing due to the increasing prevalence of chronic diseases and aging populations across the globe. On other hand, the continuous COVID-19 supply challenges has increased the demand for ventilators.
The Netherlands respiratory devices market has been segmented on the basis of
Key players competing in the Netherlands respiratory devices market are GlaxoSmithKline PLC; DeVilbiss Healthcare LLC; GE Healthcare; Dragerwerk AG; Fisher & Paykel Healthcare Ltd; and Getinge AB. The market players are continuously indulging in the activities such as mergers and acquisitions, research and developments, and increasing their investments for development of innovative products.
In April 2019, Boehringer Ingelheim International GmbH contributed EUR 105 million to extend its creation sites in Dortmund and Ingelheim in Germany for improvement of respiratory pipeline items. This venture and extension can support the creation limit of cutting edge inhaler Respimat in Europe.
In September 2019, GlaxoSmithKline plc reported the US Food and Drug Administration (FDA) endorsement for its biologics Nucala (mepolizumab) for the treatment of serious eosinophilic asthma in children aged somewhere in the range of six and 11. This approval has extended the extra treatment for serious eosinophilic asthma in the US for patients.
Some other reports from this category!